Early shift from ranibizumab to aflibercept for resistant pigment epitelial detachment in classical choroidal neovascularization

Basit Öğe Kaydı
dc.authorscopusid50263136900
dc.authorscopusid57197793503
dc.contributor.authorSever, Özkan
dc.contributor.authorHorozoğlu, Fatih
dc.date.accessioned2022-05-11T14:35:47Z
dc.date.available2022-05-11T14:35:47Z
dc.date.issued2017
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalı
dc.description.abstractAIM: To evaluate the therapeutic effect of aflibercept in patients with suboptimal response to ranibizumab therapy in the early period. METHOD: Thirty-eight patients with wet type age related macular degeneration(W-AMD) were involved in this study. Eighteen patients with suboptimal response were shifted to 3 doses monthly intravitreal aflibercept therapy (IVA) and left 20 patients with suboptimal response went on 3 more monthly intravitreal ranibizumab (IVR). All changes were evaluated with fluorescein anigography (FA) and optical coherence tomography (OCT). RESULTS: Preoperative mean visual acuity (VA) and central macular thickness (CMT) of patients were 0.84±0.47 logMAR and 360±84 ?m, respectively. One month after last IVR and IVA treatments, VA of patients were 1.1±0.34 (P=0.11) logMAR and 0.48±0.37 (P=0.019) logMAR and CMTs were 300±79 ?m (P=0.002) and 271±51 ?m (P=0.002), respectively. CONCLUSION: To eliminate repeated therapy for patients with suboptimal response to ranibizumab therapy, aflibercept might be a good alternative for early visual rehabilitation. Copyright 2017 by the IJO Press.
dc.identifier.doi10.3980/j.issn.1672-5123.2017.10.03
dc.identifier.endpage1816
dc.identifier.issn1672-5123
dc.identifier.issue10en_US
dc.identifier.scopus2-s2.0-85034849624
dc.identifier.scopusqualityQ4
dc.identifier.startpage1812
dc.identifier.urihttps://doi.org/10.3980/j.issn.1672-5123.2017.10.03
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8216
dc.identifier.volume17
dc.indekslendigikaynakScopus
dc.institutionauthorSever, Özkan
dc.institutionauthorHorozoğlu, Fatih
dc.language.isoen
dc.publisherInternational Journal of Ophthalmology (c/o Editorial Office)
dc.relation.ispartofInternational Eye Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAflibercept
dc.subjectChoroidal neovascularization
dc.subjectEarly
dc.subjectResistance
dc.subjectSuboptimal response
dc.subjectaflibercept
dc.subjectranibizumab
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectasthma
dc.subjectcentral macular thickness
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectdrug efficacy
dc.subjectdrug substitution
dc.subjectdrug withdrawal
dc.subjectfemale
dc.subjectfluorescence angiography
dc.subjecthuman
dc.subjectmale
dc.subjectoptical coherence tomography
dc.subjectpigment epithelium
dc.subjectsubretinal neovascularization
dc.subjecttreatment outcome
dc.subjecttreatment response
dc.subjectvisual acuity
dc.subjectwet macular degeneration
dc.titleEarly shift from ranibizumab to aflibercept for resistant pigment epitelial detachment in classical choroidal neovascularization
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu